Largest Negative One-Day Changes for PCSA

How does PCSA usually behave after a large single-day down move in the stock price?

Using the 12 largest single-day down moves over the last 3 years in PCSA stock, the average move was -32.2% with the single largest daily move of -47.6% occurring on 15-Dec-2025. The following day, PCSA stock price averaged -4.8% losses, with down moves exceeding up moves. The stock was down 75% of the time in that period one day after these significant moves. Earnings dates have been excluded from this analysis.

Catalysts

7 of the moves coincided with a company-issued press release.

1 Week After

The following week, PCSA stock price averaged +198.3% gains, with down moves exceeding up moves across 12 observations. The stock was down 67% of the time in that period one week following these significant moves.

Full Data Set is Available for Premium Subscribers

From Start
of Range:

To End
of Range:

Cancel

Stock Price Performance - 12 Largest Negative One-Day Changes
		Before Event Date (Not Including Day of Selected Event)					Day of Event					After Event Date (Not Including Day of Selected Event)					Custom Range▾
Date	Note	2 Weeks	1 Week	3 Days	2 Days	1 Day	Day-Of Move	Opening Gap	% Open-to-High	% Open-to-Low	Drift Open-to-Close	1 Day	2 Days	3 Days	1 Week	2 Weeks	2 Days Before to 2 Days After
19-Mar-2026 [Stock -26.3%]							-26.3%
18-Dec-2025 [Stock -41.6%]	Press Release Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer (17-Dec-2025, 8:00 AM Globe Newswire)						-41.6%
15-Dec-2025 [Stock -47.6%]							-47.6%
13-Jun-2025 [Stock -24.9%]	Press Release Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025 (13-Jun-2025, 8:00 AM Globe Newswire)						-24.9%
2-Apr-2025 [Stock -27.2%]							-27.2%
10-Apr-2024 [Stock -36.8%]							-36.8%
29-Jan-2024 [Stock -24.3%]	Press Release Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering (26-Jan-2024, 9:04 AM Globe Newswire)						-24.3%
26-Jan-2024 [Stock -28.0%]	Press Releases Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses (25-Jan-2024, 8:30 AM Globe Newswire) Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering (26-Jan-2024, 9:04 AM Globe Newswire)						-28.0%
22-Jan-2024 [Stock -44.3%]	Press Release Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer (19-Jan-2024, 7:45 AM Globe Newswire)						-44.3%
18-Jan-2024 [Stock -25.3%]	Press Release Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split (18-Jan-2024, 7:45 AM Globe Newswire)						-25.3%
13-Dec-2023 [Stock -25.4%]	Press Release Processa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation Capecitabine (13-Dec-2023, 9:00 AM Globe Newswire)						-25.4%
20-Oct-2023 [Stock -34.1%]							-34.1%
Simple Average Returns - 12 Largest Negative One-Day Changes
Avg Return
Positive Occurrences
Negative Occurrences
Absolute Average Returns - 12 Largest Negative One-Day Changes
Abs Avg Return
Max Abs Return
Min Abs Return
Median, Minimum, and Maximum Returns - 12 Largest Negative One-Day Changes
Median Return
Max Positive Return
Max Negative Return